Combination therapy for treating cancer

Patent metadata

Field	Value
Publication number	US-11370781-B2
Application number	US-202016985404-A
Country	US
Kind code	B2
Filing date	Aug 5, 2020
Priority date	Apr 13, 2012
Publication date	Jun 28, 2022
Grant date	Jun 28, 2022

Abstract

The present invention relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

First claim

What is claimed is:

1. A pack or container comprising: (i) a pharmaceutical composition comprising a compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein
each of R a and R b , independently, is H or C 1 -C 6 alkyl, or R a and R b , together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, wherein the C 1 -C 5 alkyl or 4 to 7-membered ring is optionally substituted with one or more -Q 3 -T 3 , in which Q 3 is a bond or unsubstituted or substituted C 1 -C 3 alkyl linker, and T 3 is H, halo, 4 to 7-membered heterocycloalkyl, C 1 -C 3 alkyl, OR d , COOR d , —S(O) 2 R d , or —NR d R e , in which each of R d and R e is independently H or C 1 -C 6 alkyl, or -Q 3 T 3 is oxo;
R 7 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q 5 -T 5 , in which Q 5 is a bond, C(O), C(O)NR k , NR k C(O), S(O) 2 , or C 1 -C 3 alkyl linker, R k being H or C 1 -C 6 alkyl, and T 5 is H, halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O) q R q in which q is 0, 1, or 2 and R q is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T 5 is optionally substituted with one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T 5 is H, halo, hydroxyl, or cyano; or -Q 5 -T 5 is oxo; and
R 8 is H, methyl, or ethyl; and
(ii) a pharmaceutical composition comprising rituximab.

2. The pack or container of claim 1 , further comprising (iii) a pharmaceutical composition comprising lenalidomide.

3. The pack or container of claim 1 , wherein the compound of Formula (IIa) is Compound 44:

or a pharmaceutically acceptable salt thereof.

4. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, which is optionally substituted with one or more -Q 3 -T 3 .

5. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahydrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, or morpholinyl, each of which is optionally substituted with one or more -Q 3 -T 3 .

6. The pack or container of claim 5 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form morpholinyl.

7. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 7 is 4 to 7-membered heterocycloalkyl optionally substituted with one or more -Q 5 -T 5 .

8. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 7 is piperidinyl, tetrahydropyranyl, cyclopentyl, or cyclohexyl, each optionally substituted with one -Q 5 -T 5 .

9. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 7 is tetrahydropyranyl.

10. The pack or container of claim 1 , wherein in the compound of Formula (IIa), R 8 is H, methyl, or ethyl.

11. A pack or container comprising: (i) a pharmaceutical composition comprising a compound of Formula (IIa):

or a pharmaceutically acceptable salt thereof, wherein
each of R a and R b , independently, is H or C 1 -C 6 alkyl, or R a and R b , together with the N atom to which the are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, wherein the C 1 -C 6 alkyl or 4 to 7-membered ring is optionally substituted with one or more -Q 3 -T 3 , in which Q 3 is a bond or unsubstituted or substituted C 1 -C 3 alkyl linker, and T 3 is H, halo, 4 to 7-membered heterocycloalkyl, C 1 -C 3 alkyl, OR d , COOR d , —S(O) 2 R d , or —NR d R e , in which each of R d and R e is independently H or C 1 -C 6 alkyl, or -Q 3 T 3 is oxo;
R 7 is C 1 -C 6 alkyl, C 3 -C 8 cycloalkyl, or 4 to 12-membered heterocycloalkyl, each optionally substituted with one or more -Q 5 -T 5 , in which Q 5 is a bond, C(O), C(O)NR k , NR k C(O), S(O) 2 , or C 1 -C 3 alkyl linker, R k being H or C 1 -C 6 alkyl, and T 5 is H, halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, 5- or 6-membered heteroaryl, or S(O) q R q in which q is 0, 1, or 2 and R q is C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, or 5- or 6-membered heteroaryl, and T 5 is optionally substituted with one or more substituents selected from the group consisting of halo, C 1 -C 6 alkyl, hydroxyl, cyano, C 1 -C 6 alkoxyl, amino, mono-C 1 -C 6 alkylamino, di-C 1 -C 6 alkylamino, C 3 -C 8 cycloalkyl, C 6 -C 10 aryl, 4 to 12-membered heterocycloalkyl, and 5- or 6-membered heteroaryl except when T 5 is H, halo, hydroxyl, or cyano; or -Q 5 -T 5 is oxo; and
R 8 is H, methyl, or ethyl; and
(ii) a pharmaceutical composition comprising lenalidomide.

12. The pack or container of claim 11 , further comprising (iii) a pharmaceutical composition comprising rituximab.

13. The pack or container of claim 11 , wherein the compound of Formula (IIa) is Compound 44:

or a pharmaceutically acceptable salt thereof.

14. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form a 4 to 7-membered heterocycloalkyl ring having 0 or 1 additional heteroatom, which is optionally substituted with one or more -Q 3 -T 3 .

15. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form azetidinyl, pyrrolidinyl, imidazolidinyl, pyrazolidinyl, oxazolidinyl, isoxazolidinyl, triazolidinyl, tetrahydrofuranyl, piperidinyl, 1,2,3,6-tetrahydropyridinyl, piperazinyl, or morpholinyl, each of which is optionally substituted with one or more -Q 3 -T 3 .

16. The pack or container of claim 15 , wherein in the compound of Formula (IIa), R a and R b , together with the N atom to which they are attached, form morpholinyl.

17. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R 7 is 4 to 7-membered heterocycloalkyl optionally substituted with one or more -Q 5 -T 5 .

18. The pack or container of claim 11 , wherein in the compound of Formula (IIa), R 7 is piperidinyl, tetrahydropyranyl, cyclopentyl, or cyclohexyl, each opt

Assignees

• Epizyme Inc

Inventors

• Keilhack Heike
• Knutson Sarah Kathleen
• Kuntz Kevin Wayne

Classifications

• C07D413/12

  linked by a chain containing hetero atoms as chain links · CPC title

• A61K31/553

  having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine · CPC title

• A61K31/5386

  spiro-condensed or forming part of bridged ring systems · CPC title

• A61K31/4433

  containing a six-membered ring with oxygen as a ring hetero atom · CPC title

• A61K31/397

  having four-membered rings, e.g. azetidine · CPC title